Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.
Matrix metalloproteinases (MMPs) and related enzymes (ADAMs, ADAMTS) and their inhibitors control matrix turnover and function. Recent advances in our understanding of musculoskeletal conditions such as tendinopathy, arthritis, Dupuytren's disease, degenerative disc disease, and bone and soft tissue healing suggest that MMPs have prominant roles. Importantly, MMPs are amenable to inhibition by cheap, safe, and widely available drugs such as the tetracycline antibiotics and the bisphosphonates. This indicates that these MMP inhibitors, if proven effective for any novel indication, may be quickly brought into clinical practice.
Pasternak
Björn
B
Orthopaedics and Sports Medicine, IKE, Linköping University, Linköping, Sweden. bjorn.pasternak@gmail.com
Aspenberg
Per
P
D051722:ADAM Proteins / Q000378:metabolism / Q000627:therapeutic use; D000071097:ADAMTS1 Protein; D001857:Bone Matrix / Q000201:enzymology / Q000502:physiology; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism / Q000627:therapeutic use; D009140:Musculoskeletal Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology*; D011379:Prognosis; D013754:Tetracyclines / Q000627:therapeutic use; D016896:Treatment Outcome
D004164:Diphosphonates; D061965:Matrix Metalloproteinase Inhibitors; D013754:Tetracyclines; D051722:ADAM Proteins; D000071097:ADAMTS1 Protein; C103859:ADAMTS1 protein, human; D020782:Matrix Metalloproteinases